Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + mFOLFOX6 in Metastatic Colorectal Cancer
NCT02384850Phase 1Terminated
- Sponsor
- GSO Global Clinical Research
- Start
- Mar 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of selinexor in metastatic colorectal cancer (mCRC), sponsored by GSO Global Clinical Research. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Mar 2015; status: terminated.
02
Drugs
selinexor
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02384850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02384850.